Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Colorectal Neoplasms 6 Carcinoma, Hepatocellular 4 Sarcoma 2 Rectal Neoplasms 2 Neoplasms 2 Neoplasm Metastasis 2 Gastrointestinal Stromal Tumors 2 Solid Malignant Tumors 1 Sarcoma, Ewing 1 Recurrence 1 Piebaldism 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Osteosarcoma 1 Multiple Myeloma 1 Meningioma 1 Lymphoma, Non-Hodgkin 1 Lung Neoplasms 1 HER2 IHC3+ Advanced Colorectal Cancer 1 Glioblastoma 1 Disease Progression 1 Cholangiocarcinoma 1 Bone Neoplasms 1

Interventions

Cyclophosphamide 26 fludarabine 18 Dexamethasone 17 pembrolizumab 12 Rituximab 11 Etoposide 10 venetoclax 9 pomalidomide 9 Gemcitabine 9 fludarabine phosphate 7 daratumumab 7 Lenalidomide 7 Bortezomib 7 carfilzomib 6 obinutuzumab 5 glofitamab 5 Vincristine 5 Temozolomide 5 Prednisone 5 Nivolumab 5 Immunotherapy, Adoptive 5 Cisplatin 5 Calcium Dobesilate 5 selinexor 4 cemiplimab 4 Doxorubicin 4 Cytarabine 4 Carboplatin 4 zanubrutinib 3 ruxolitinib 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recurrence × regorafenib × 90 days × Clear all

NCT03970447 2026-06-03

GBM AGILE

Global Coalition for Adaptive Research

Phase 2/3 Recruiting

Glioblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡